Abraham SILVA CARMONA, Hugo MENDIETA ZERÓN

NF-κΒ and SOD expression in preeclamptic placentas

Background/aim: Preeclampsia is a leading cause of maternal death in the developing world. Our aim was to quantify and compare messenger (mRNA) expression of nuclear factor-kappa beta (NF-κΒ) and superoxide dismutase (SOD) in control patients with preeclampsia and without preeclampsia with or without familial hereditary background. Materials and methods: Four groups of patients were formed depending on the presence or absence of preeclampsia and presence or absence of familial history for preeclampsia. NF-κΒ and SOD were measured in human placentas by real-time quantitative polymerase chain reaction. The 2 ΔΔct analysis method was used to measure the difference in the relative expression of the target genes in each group of patients. Results: In NF-κΒ expression, there was an increase of 23.35% in the group of women with preeclampsia versus women with preeclampsia without familial history. Regarding SOD, there was a reduction of about 33.33% in the expression in women with preeclampsia with familial history versus women with preeclampsia without familial history. Conclusion: Familial presence of preeclampsia could predispose to altered expression in SOD and NF-κΒ.

PDF

___

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33: 130-137.
2. van Dijk MG, Díaz Olavarrieta C, Zuñiga PU, Gordillo RL, Gutiérrez ME, García SG. Use of magnesium sulfate for treatment of pre-eclampsia and eclampsia in Mexico. Int J Gynaecol Obs 2013; 121: 110-114.
3. Romero-Arauz JF1, Morales-Borrego E, García-Espinosa M, Peralta-Pedrero ML. Clinical guideline. Preeclampsiaeclampsia. Rev Med Inst Mex Seguro Soc 2012; 50: 569-579 (in Spanish with English abstract).
4. Carr DB, Epplein M, Johnson CO, Easterling TR, Critchlow CW. A sisters risk: family history as a predictor of preeclampsia. Am J Obs Gynecol 2005; 193: 965-972.
5. Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, Varner MW. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med 2001; 344: 867- 872.
6. Kaur G, Mishra S, Sehgal A, Prasad R. Alterations in lipid peroxidation and antioxidant status in pregnancy with preeclampsia. Mol Cell Biochem 2008; 313: 37-44.
7. Vanderlelie J, Gude N, Perkins AV. Antioxidant gene expression in preeclamptic placentae: a preliminary investigation. Placenta 2008; 29: 519-522.
8. Kurlak LO, Green A, Loughna P, Broughton Pipkin F. Oxidative stress markers in hypertensive states of pregnancy: preterm and term disease. Front Physiol 2014; 5: 310.
9. Tortladze M, Kintraia N, Parkauli M, Sanikidze T. Blood antioxidant enzyme activity during physiological and preeclampsia syndrome complicated pregnancy. Georg Med News 2013; 215: 12-16 (in Russian with English abstract).
10. Dennery PA. Effects of oxidative stress on embryonic development. Birth Defects Res C Embryo Today 2007; 81: 155-162.
11. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012; 24: 981-990.
12. Siomek A. NF-κB signaling pathway and free radical impact. Acta Biochim Pol 2012; 59: 323-331.
13. Winyard PG, Blake DR. Antioxidants, redox-regulated transcription factors, and inflammation. Adv Pharmacol 1997; 38: 403-421.
14. ACOG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99: 159-167.
15. Valenzuela FJ, Pérez-Sepúlveda A, Torres MJ, Correa P, Repetto GM, Illanes SE. Pathogenesis of preeclampsia: the genetic component. J Pregnancy 2012: 2012: 632732.
16. Salonen Ros H, Lichtenstein P, Lipworth L, Cnattingius S. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet 2000; 91: 256-260.
17. Dekker G, Robillard PY, Roberts C. The etiology of preeclampsia: the role of the father. J Reprod Immunol 2011; 89: 126-132.
18. Goddard KA, Tromp G, Romero R, Olson JM, Lu Q, Xu Z, Parimi N, Nien JK, Gomez R, Behnke E et al. Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered 2007; 63: 1-16.
19. Mutze S, Rudnik-Schoneborn S, Zerres K, Rath W. Genes and the preeclampsia syndrome. J Perinat Med 2008; 36: 38-58. 20. Staines-Urias E, Páez MC, Doyle P, Dudbridge F, Serrano NC, Ioannidis JP, Keating BJ, Hingorani AD, Casas JP. Genetic association studies in pre-eclampsia: systematic meta-analyses and field synopsis. Int J Epidemiol 2012; 41: 1764-1775.
21. Vaiman D, Calicchio R, Miralles F. Landscape of transcriptional deregulations in the preeclamptic placenta. PLoS One 2013; 8: e65498.
22. Vasarhelyi B, Cseh A, Kocsis I, Treszl A, Györffy B, Rigó J Jr. Three mechanisms in the pathogenesis of pre-eclampsia suggested by over-represented transcription factor-binding sites detected with comparative promoter analysis. Mol Hum Reprod 2006; 12: 31-34.
23. Basar M, Yen CF, Buchwalder LF, Murk W, Huang SJ, Godlewski K, Kocamaz E, Arda O, Schatz F, Lockwood CJ et al. Preeclampsia-related increase of interleukin-11 expression in human decidual cells. Reproduction 2010; 140: 605-612.
24. Williams PJ, Broughton Pipkin F. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pr Res Clin Obs Gynaecol 2011; 25: 405-417.
25. Zusterzeel PL, Rütten H, Roelofs HM, Peters WH, Steegers EA. Protein carbonyls in decidua and placenta of pre-eclamptic women as markers for oxidative stress. Placenta 2001; 22: 213- 219.
26. Kashanian M, Aghbali F, Mahali N. Evaluation of the diagnostic value of the first-trimester maternal serum high-sensitivity C-reactive protein level for prediction of pre-eclampsia. J Obs Gynaecol Res 2013; 39: 1549-1554.